Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group

William Sause, Patricia Kolesar, Samuel Taylor IV, David Johnson, Robert B Livingston, Ritsuko Komaki, Bahman Emami, Walter Curran, Roger Byhardt, A. Rashid Dar, Andrew Turrisi

Research output: Contribution to journalArticle

562 Citations (Scopus)

Abstract

Study objectives: The purpose of this phase III clinical trial was to test whether chemotherapy followed by radiation therapy resulted in superior survival to either hyperfractionated radiation or standard radiation in surgically unresectable non-small cell lung cancer. Design: Patients were prospectively randomized to 2 months of cisplatin, vinblastine chemotherapy followed by 60 Gy of radiation at 2.0 Gy per fraction or 1.2 Gy per fraction radiation delivered twice daily to a total dose of 69.6 Gy, or 2.0 Gy per fraction of radiation once daily to 60 Gy. Patients were enrolled from January 1989 through January 1992, and followed for a potential minimum period of 5 years. Setting: This trial was an intergroup National Cancer Institute-funded trial within the Radiation Therapy Oncology Group, the Eastern Cooperative Oncology Group, and the Southwest Oncology Group. Patients: Patients with surgically unresectable non-small cell lung cancer, clinical stage II, IIIA, and IIIB, were required to have a Karnofsky Performance Status of ≥ 70 and a weight loss of < 5% for 3 months before study entry. Four hundred ninety patients were registered on trial, of which 458 patients were eligible. Conclusion: Overall survival was statistically superior for the patients receiving chemotherapy and radiation vs the other two arms of the study. The twice-daily radiation therapy arm, although better, was not statistically superior in survival for those patients receiving standard radiation. Median survival for standard radiation was 11.4 months; for chemotherapy and irradiation, 13.2 months; and for hyperfractionated irradiation, 12 months. The respective 5-year survivals were 5% for standard radiation therapy, 8% for chemotherapy followed by radiation therapy, and 6% for hyperfractionated irradiation.

Original languageEnglish (US)
Pages (from-to)358-364
Number of pages7
JournalChest
Volume117
Issue number2
StatePublished - 2000
Externally publishedYes

Fingerprint

Radiation Oncology
Non-Small Cell Lung Carcinoma
Radiotherapy
Radiation
Drug Therapy
Survival
Karnofsky Performance Status
Radiation Dosage
Phase III Clinical Trials
National Cancer Institute (U.S.)
Vinblastine
Cisplatin
Weight Loss

Keywords

  • Chemotherapy
  • Hyperfractionated radiation
  • Lung cancer
  • Phase III trial
  • Radiation

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer : Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. / Sause, William; Kolesar, Patricia; Taylor IV, Samuel; Johnson, David; Livingston, Robert B; Komaki, Ritsuko; Emami, Bahman; Curran, Walter; Byhardt, Roger; Rashid Dar, A.; Turrisi, Andrew.

In: Chest, Vol. 117, No. 2, 2000, p. 358-364.

Research output: Contribution to journalArticle

Sause, W, Kolesar, P, Taylor IV, S, Johnson, D, Livingston, RB, Komaki, R, Emami, B, Curran, W, Byhardt, R, Rashid Dar, A & Turrisi, A 2000, 'Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group', Chest, vol. 117, no. 2, pp. 358-364.
Sause, William ; Kolesar, Patricia ; Taylor IV, Samuel ; Johnson, David ; Livingston, Robert B ; Komaki, Ritsuko ; Emami, Bahman ; Curran, Walter ; Byhardt, Roger ; Rashid Dar, A. ; Turrisi, Andrew. / Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer : Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. In: Chest. 2000 ; Vol. 117, No. 2. pp. 358-364.
@article{f0c3c6eb5d7b4fc798879d6aa70e23ab,
title = "Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group",
abstract = "Study objectives: The purpose of this phase III clinical trial was to test whether chemotherapy followed by radiation therapy resulted in superior survival to either hyperfractionated radiation or standard radiation in surgically unresectable non-small cell lung cancer. Design: Patients were prospectively randomized to 2 months of cisplatin, vinblastine chemotherapy followed by 60 Gy of radiation at 2.0 Gy per fraction or 1.2 Gy per fraction radiation delivered twice daily to a total dose of 69.6 Gy, or 2.0 Gy per fraction of radiation once daily to 60 Gy. Patients were enrolled from January 1989 through January 1992, and followed for a potential minimum period of 5 years. Setting: This trial was an intergroup National Cancer Institute-funded trial within the Radiation Therapy Oncology Group, the Eastern Cooperative Oncology Group, and the Southwest Oncology Group. Patients: Patients with surgically unresectable non-small cell lung cancer, clinical stage II, IIIA, and IIIB, were required to have a Karnofsky Performance Status of ≥ 70 and a weight loss of < 5{\%} for 3 months before study entry. Four hundred ninety patients were registered on trial, of which 458 patients were eligible. Conclusion: Overall survival was statistically superior for the patients receiving chemotherapy and radiation vs the other two arms of the study. The twice-daily radiation therapy arm, although better, was not statistically superior in survival for those patients receiving standard radiation. Median survival for standard radiation was 11.4 months; for chemotherapy and irradiation, 13.2 months; and for hyperfractionated irradiation, 12 months. The respective 5-year survivals were 5{\%} for standard radiation therapy, 8{\%} for chemotherapy followed by radiation therapy, and 6{\%} for hyperfractionated irradiation.",
keywords = "Chemotherapy, Hyperfractionated radiation, Lung cancer, Phase III trial, Radiation",
author = "William Sause and Patricia Kolesar and {Taylor IV}, Samuel and David Johnson and Livingston, {Robert B} and Ritsuko Komaki and Bahman Emami and Walter Curran and Roger Byhardt and {Rashid Dar}, A. and Andrew Turrisi",
year = "2000",
language = "English (US)",
volume = "117",
pages = "358--364",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "2",

}

TY - JOUR

T1 - Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer

T2 - Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group

AU - Sause, William

AU - Kolesar, Patricia

AU - Taylor IV, Samuel

AU - Johnson, David

AU - Livingston, Robert B

AU - Komaki, Ritsuko

AU - Emami, Bahman

AU - Curran, Walter

AU - Byhardt, Roger

AU - Rashid Dar, A.

AU - Turrisi, Andrew

PY - 2000

Y1 - 2000

N2 - Study objectives: The purpose of this phase III clinical trial was to test whether chemotherapy followed by radiation therapy resulted in superior survival to either hyperfractionated radiation or standard radiation in surgically unresectable non-small cell lung cancer. Design: Patients were prospectively randomized to 2 months of cisplatin, vinblastine chemotherapy followed by 60 Gy of radiation at 2.0 Gy per fraction or 1.2 Gy per fraction radiation delivered twice daily to a total dose of 69.6 Gy, or 2.0 Gy per fraction of radiation once daily to 60 Gy. Patients were enrolled from January 1989 through January 1992, and followed for a potential minimum period of 5 years. Setting: This trial was an intergroup National Cancer Institute-funded trial within the Radiation Therapy Oncology Group, the Eastern Cooperative Oncology Group, and the Southwest Oncology Group. Patients: Patients with surgically unresectable non-small cell lung cancer, clinical stage II, IIIA, and IIIB, were required to have a Karnofsky Performance Status of ≥ 70 and a weight loss of < 5% for 3 months before study entry. Four hundred ninety patients were registered on trial, of which 458 patients were eligible. Conclusion: Overall survival was statistically superior for the patients receiving chemotherapy and radiation vs the other two arms of the study. The twice-daily radiation therapy arm, although better, was not statistically superior in survival for those patients receiving standard radiation. Median survival for standard radiation was 11.4 months; for chemotherapy and irradiation, 13.2 months; and for hyperfractionated irradiation, 12 months. The respective 5-year survivals were 5% for standard radiation therapy, 8% for chemotherapy followed by radiation therapy, and 6% for hyperfractionated irradiation.

AB - Study objectives: The purpose of this phase III clinical trial was to test whether chemotherapy followed by radiation therapy resulted in superior survival to either hyperfractionated radiation or standard radiation in surgically unresectable non-small cell lung cancer. Design: Patients were prospectively randomized to 2 months of cisplatin, vinblastine chemotherapy followed by 60 Gy of radiation at 2.0 Gy per fraction or 1.2 Gy per fraction radiation delivered twice daily to a total dose of 69.6 Gy, or 2.0 Gy per fraction of radiation once daily to 60 Gy. Patients were enrolled from January 1989 through January 1992, and followed for a potential minimum period of 5 years. Setting: This trial was an intergroup National Cancer Institute-funded trial within the Radiation Therapy Oncology Group, the Eastern Cooperative Oncology Group, and the Southwest Oncology Group. Patients: Patients with surgically unresectable non-small cell lung cancer, clinical stage II, IIIA, and IIIB, were required to have a Karnofsky Performance Status of ≥ 70 and a weight loss of < 5% for 3 months before study entry. Four hundred ninety patients were registered on trial, of which 458 patients were eligible. Conclusion: Overall survival was statistically superior for the patients receiving chemotherapy and radiation vs the other two arms of the study. The twice-daily radiation therapy arm, although better, was not statistically superior in survival for those patients receiving standard radiation. Median survival for standard radiation was 11.4 months; for chemotherapy and irradiation, 13.2 months; and for hyperfractionated irradiation, 12 months. The respective 5-year survivals were 5% for standard radiation therapy, 8% for chemotherapy followed by radiation therapy, and 6% for hyperfractionated irradiation.

KW - Chemotherapy

KW - Hyperfractionated radiation

KW - Lung cancer

KW - Phase III trial

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=0033993435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033993435&partnerID=8YFLogxK

M3 - Article

C2 - 10669675

AN - SCOPUS:0033993435

VL - 117

SP - 358

EP - 364

JO - Chest

JF - Chest

SN - 0012-3692

IS - 2

ER -